(Reuters) -The U.S. Food and Drug Administration has approved Kura Oncology’s drug to treat a rare form of blood cancer that has returned or resisted initial therapy, the regulator said on Thursday.
The once-daily pill, ziftomenib, is the first approved therapy for acute myeloid leukemia patients with an NPM1 mutation, a genetic change found in about 30% of cases.
The approval offers new hope for patients with a particularly aggressive form of blood cancer who have exhausted other treatment options.
The drug works by blocking menin, a protein that plays a role in cancer cell growth.
Shares of the company were up about 1% in morning trading.
(Reporting by Kamal Choudhury and Christy Santhosh in Bengaluru; Editing by Shailesh Kuber)
Brought to you by www.srnnews.com
